Company intelligence / Profile preview
MapLight Therapeutics
Palo Alto / Burlington*, California / Massachusetts*, United Statesmaplightrx.com ↗
- Ownership
- Public · MPLT
- Employees
- ~55
- Development stage
- Other
01
Overview
MapLight has advanced a robust pipeline with two product candidates in the clinic. Lead candidate ML‑007C‑MA (a muscarinic agonist) entered Phase 2 trials for schizophrenia and Alzheimer’s disease psychosis in 2024. The company leverages a circuit-based approach to develop targeted therapies for CNS disorders with significant unmet need. Clinical data from similar mechanisms suggest strong efficacy with improved side effect profiles compared to traditional antipsychotics
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Financials
- Market cap
- $265.1M
- Total revenue
- $0
- Enterprise value
- $-37.7M
Beyond the preview
Go deeper on MapLight Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MapLight Therapeutics.